Ipratropium Bromide
Ipratropium bromide is an anticholinergic (parasympatholytic) agent that inhibits vagally-mediated reflexes by antagonizing the action of acetylcholine. This action prevents the increase in intracellular concentration of cyclic guanosine monophosphate (cGMP) caused by interaction of acetylcholine with muscarinic receptors on bronchial smooth muscle, leading to bronchodilation.
Dosage by Body Weight
Administered via oral inhalation (using a metered-dose inhaler or nebulizer) or intranasally. Dosage must be individualized. Inhalation solution is typically administered 3 to 4 times a day via nebulizer. Pediatric dosing is often based on age and severity of symptoms rather than strict body weight; consult a healthcare professional for exact instructions.
- Body Weight
- Below 5 kg
- Dose
- Not routine
- Frequency
- Use only if prescribed
- Tracking Notes
- Safety and effectiveness in infants under 5 kg have not been established. Use strictly under specialist supervision.
- Body Weight
- 5-7 kg
- Dose
- 125 mcg to 250 mcg (via nebulization)
- Frequency
- Every 6 to 8 hours as needed
- Tracking Notes
- Mainly used under close medical supervision for acute, severe bronchospasm.
- Body Weight
- 8-10 kg
- Dose
- 125 mcg to 250 mcg (via nebulization)
- Frequency
- Every 6 to 8 hours as needed
- Tracking Notes
- May be combined with a beta2-agonist (such as albuterol) for synergistic bronchodilation in acute settings.
- Body Weight
- 11-15 kg
- Dose
- 250 mcg (via nebulization)
- Frequency
- Every 6 to 8 hours
- Tracking Notes
- Standard pediatric dose for acute asthma exacerbations in children. Administer over 5-15 minutes.
- Body Weight
- 16-20 kg
- Dose
- 250 mcg (via nebulization)
- Frequency
- Every 6 to 8 hours
- Tracking Notes
- Dilute with sterile normal saline if volume adjustment is necessary for nebulizer operation.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine | Use only if prescribed | Safety and effectiveness in infants under 5 kg have not been established. Use strictly under specialist supervision. |
| 5-7 kg | 125 mcg to 250 mcg (via nebulization) | Every 6 to 8 hours as needed | Mainly used under close medical supervision for acute, severe bronchospasm. |
| 8-10 kg | 125 mcg to 250 mcg (via nebulization) | Every 6 to 8 hours as needed | May be combined with a beta2-agonist (such as albuterol) for synergistic bronchodilation in acute settings. |
| 11-15 kg | 250 mcg (via nebulization) | Every 6 to 8 hours | Standard pediatric dose for acute asthma exacerbations in children. Administer over 5-15 minutes. |
| 16-20 kg | 250 mcg (via nebulization) | Every 6 to 8 hours | Dilute with sterile normal saline if volume adjustment is necessary for nebulizer operation. |
Formulation
Purpose
Used as a bronchodilator for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Also used off-label for acute asthma exacerbations and intranasally to treat rhinorrhea.
Generic Name
Ipratropium bromideBranded Drug Names
Ipratropium Bromide is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.